Osteosarcoma is the most common primary malignant bone tumor in children and adolescents, arising from cells that normally build bone tissue. It tends to strike during the teenage growth spurt, grows aggressively, and has a strong tendency to spread to the lungs. Thanks to modern chemotherapy and surgery, roughly half to three-quarters of patients with localized disease survive long term, but the prognosis drops sharply once the cancer has metastasized. Understanding who gets osteosarcoma, how it behaves, and how treatment has evolved gives a clearer picture of a disease that remains one of the toughest challenges in pediatric oncology.
Who Gets Osteosarcoma
Osteosarcoma follows a distinctive two-peak pattern across age groups. The first and larger peak hits adolescents, centered around ages ten to fourteen, right when the skeleton is growing fastest. That timing is not a coincidence: the rapid bone turnover of puberty appears to create a window of vulnerability for the genetic mistakes that drive the cancer.1PubMed. The epidemiology of osteosarcoma The second, smaller peak shows up in adults over sixty, and in that group it is often tied to pre-existing bone conditions like Paget’s disease, essentially making it a different biological scenario from the adolescent form.2PubMed Central. Descriptive Epidemiology of Malignant Primary Osteosarcoma Using Population-based Registries, United States, 1999-2008
Certain inherited genetic syndromes raise the risk substantially. Conditions that cause chromosomal instability or carry mutations in tumor-suppressor genes can push osteosarcoma risk well above baseline.3PubMed Central. Unraveling syndrome-driven osteosarcoma: genetic insights and therapeutic frontiers One of the most important individual genes is RB1, the retinoblastoma tumor suppressor. Loss-of-function mutations in RB1 are key drivers in many osteosarcomas and compromise the cell’s ability to maintain its own genome.4Nature Communications. Therapeutic vulnerability to PARP1,2 inhibition in RB1-mutant osteosarcoma Most cases, though, occur without any known hereditary syndrome. The tumor cells tend to be genetically chaotic, with widespread chromosomal rearrangements rather than a single neat driver mutation, which is part of why targeted therapies have been so hard to develop.
Why It Often Gets Missed at First
One of the most frustrating aspects of osteosarcoma is that its early symptoms are easy to shrug off. The typical presentation is localized bone pain, usually around the knee, in a teenager who is growing fast and probably playing sports. That description fits a dozen harmless things, from growing pains to a pulled ligament. Because of this overlap, primary care providers frequently attribute the symptoms to benign causes, and diagnosis ends up delayed.5PubMed. Missing the Malignancy in Primary Care: A Case Study on Pediatric Osteosarcoma Pain that persists for weeks without a clear injury explanation, worsens at night, or comes with swelling over a bone should prompt imaging sooner rather than later.
How It Is Diagnosed
A standard X-ray is often the first clue. Osteosarcoma produces a set of recognizable radiographic features: a “sunburst” pattern of new bone radiating outward, a triangular wedge of lifted periosteum known as Codman’s triangle, destruction of the normal bone cortex, and new bone formation extending into soft tissues.6PubMed Central. Classification, imaging, biopsy and staging of osteosarcoma When a radiologist sees that combination on a plain film, it is a strong signal pointing toward osteosarcoma even before advanced imaging or biopsy.7Journal of the Korean Orthopaedic Association. Analysis of X-Ray Findings of Osteosarcoma MRI of the affected limb and a CT scan of the chest follow, primarily to map the tumor’s extent and check for lung metastases. A tissue biopsy confirms the diagnosis: the hallmark finding is malignant cells producing osteoid, the unmineralized precursor to bone. Despite decades of study, the exact cell of origin remains debated, with evidence pointing toward an early bone-forming cell rather than a more primitive stem cell.8PubMed. Cells of origin in osteosarcoma: mesenchymal stem cells or osteoblast committed cells?
Standard Treatment
The backbone of osteosarcoma treatment has not changed dramatically in decades. The standard approach combines chemotherapy and surgery. Chemotherapy typically begins before the operation (called neoadjuvant therapy) to shrink the tumor and kill microscopic cancer cells that may have already spread. The go-to regimen is a combination of methotrexate, doxorubicin, and cisplatin, commonly called MAP.9PubMed Central. Methotrexate, Doxorubicin, and Cisplatin (MAP) Plus Maintenance Pegylated Interferon Alfa-2b Versus MAP Alone in Patients With Resectable High-Grade Osteosarcoma and Good Histologic Response to Preoperative MAP A meta-analysis comparing MAP to other drug combinations confirmed it as the preferred option, though it is worth noting that the five-year survival rates between MAP and alternative regimens were statistically similar, at about 56% in both groups across nearly 3,000 patients.10PubMed Central. Evaluating the Outcome and Patient Safety of Methotrexate, Doxorubicin, and Cisplatin Regimen for Chemotherapy in Osteosarcoma: A Meta-Analysis MAP remains standard not because it dramatically outperforms alternatives, but because nothing tested so far has convincingly beaten it, and adding extra drugs has mostly added toxicity without clear survival benefit.11PubMed Central. Methotrexate, doxorubicin, and cisplatinum regimen is still the preferred option for osteosarcoma chemotherapy: A meta-analysis and clinical observation
What Tumor Necrosis Tells Doctors
After the initial rounds of chemotherapy, the tumor is surgically removed. At that point, a pathologist examines the resected specimen to see how much of the tumor was killed by chemotherapy. This measurement, reported as percent tumor necrosis, is one of the strongest prognostic indicators in osteosarcoma. Patients who achieve at least 90% necrosis, meaning the chemotherapy destroyed the vast majority of cancer cells, have markedly better outcomes. In one large study, patients with less than 90% necrosis faced roughly double the risk of death compared to those with 90% or higher necrosis.12PubMed Central. Ninety Percent or Greater Tumor Necrosis Is Associated With Survival and Social Determinants of Health in Patients With Osteosarcoma in the National Cancer Database
This finding holds across the two most common histological subtypes, osteoblastic and chondroblastic osteosarcoma, though the effect appears stronger and more statistically reliable in the osteoblastic form.13PubMed. Tumor necrosis drives prognosis in osteosarcoma: No difference in chemotherapy response and survival between chondroblastic and osteoblastic osteosarcoma A multicenter study from Greece reinforced that 90% or greater necrosis was significantly associated with longer disease-free survival, though overall survival in that cohort did not reach statistical significance, likely due to sample size.14PubMed Central. Real World Data from Patients With Osteosarcoma Treated in 8 Medical Centers in Greece: Ninety Percent or Greater Tumor Necrosis Is Associated With Disease-free Survival The frustrating part is that for patients who respond poorly to chemotherapy, there is no proven second-line regimen that reliably rescues the situation. This is one of the field’s most pressing unresolved problems.
Surgical Options Beyond Amputation
Surgery for osteosarcoma has shifted dramatically over the past few decades. Where amputation was once the default, limb-salvage surgery is now the goal for most patients. In a limb-salvage procedure, the section of bone containing the tumor is removed and replaced, usually with a metal endoprosthesis or sometimes with a bone graft. For the majority of patients, this preserves a functional limb without compromising cancer outcomes.
For some patients, however, limb salvage is not possible. The tumor may be too large, involve too much soft tissue, or be in a location that makes reconstruction unreliable. In those cases, amputation remains an option, as does a less well-known procedure called rotationplasty. In this operation, the tumor-bearing segment is removed, and the lower leg is rotated 180 degrees and reattached so that the ankle joint functions as a new knee, fitting into a below-knee prosthesis.15PubMed Central. Rotationplasty Salvage Procedure as an Effective Alternative to Femoral Amputation in an Adult With a History of Osteosarcoma: A Case Report and Review Rotationplasty delivers excellent functional results and can be particularly useful in young children, whose skeletal growth would make a standard endoprosthesis problematic, or in patients whose initial limb salvage has failed due to infection or implant complications.16PubMed. Rotationplasty in the surgical treatment plan of primary malignant bone tumors. Possibilities and limits The cosmetic appearance can be startling at first, but many patients report high levels of physical activity and satisfaction with function over time.
Lung Metastases and Their Impact
Osteosarcoma spreads through the bloodstream, and its favorite destination is the lungs. About 15-20% of patients already have visible lung metastases at the time of initial diagnosis, and the lungs are also the most common site of first recurrence.17PubMed Central. Pulmonary metastasis of osteosarcoma: multiple presentations in a single patient When lung metastases are present, surgeons often attempt to remove them (called pulmonary metastasectomy), sometimes in multiple rounds, because complete surgical resection of all visible lung disease remains one of the few strategies that can meaningfully extend survival in the metastatic setting. Without it, outcomes are grim.
Options When Osteosarcoma Comes Back
For patients whose osteosarcoma returns or progresses after standard treatment, the situation is difficult. The same MAP drugs may offer some benefit, but response rates drop with each line of therapy. This has driven interest in targeted agents, particularly tyrosine kinase inhibitors (TKIs) that block the signaling pathways cancer cells use to grow and recruit blood vessels. Clinical trials have tested several of these in patients with relapsed or inoperable osteosarcoma. Apatinib monotherapy showed about 57% of patients free of progression at four months and a median overall survival of about ten months. Regorafenib achieved a median progression-free survival of about 3.6 months and overall survival of about eleven months. Cabozantinib kept roughly 71% of patients progression-free at four months, with a median progression-free survival of about 6.7 months.18PubMed Central. Tyrosine kinase inhibitors in osteosarcoma: Adapting treatment strategies These are modest numbers compared to what you see in many other cancers, but they represent real options for patients who have exhausted standard chemotherapy. Combining TKIs with chemotherapy appears to outperform TKIs alone, which may shape future trial designs.
Why Immunotherapy Has Been Slow to Deliver
Immunotherapy has transformed treatment for cancers like melanoma and lung cancer, but osteosarcoma has been stubbornly resistant. Part of the reason lies in the tumor microenvironment. Osteosarcoma creates a uniquely hostile landscape for immune cells, embedded in a mineralized bone-like matrix and populated with cells that actively suppress immune activity and help the cancer evade detection.19PubMed Central. Unlocking the tumor-immune microenvironment in osteosarcoma: insights into the immune landscape and mechanisms The tumor is infiltrated by different populations of macrophages, some of which appear to have opposing functions, and the balance between these populations may influence whether the immune system fights the tumor or unwittingly supports it.20PubMed Central. Characterization of Macrophages and Osteoclasts in the Osteosarcoma Tumor Microenvironment at Diagnosis: New Perspective for Osteosarcoma Treatment?
Immune checkpoint inhibitors, the drugs that have worked so well in other solid tumors, have shown limited activity in osteosarcoma so far. More experimental approaches are in earlier stages of development, including CAR-T cell therapy, where a patient’s own immune cells are engineered to recognize specific markers on the tumor surface. In blood cancers, CAR-T therapy has been a breakthrough, but applying it to solid tumors like osteosarcoma remains challenging because of low antigen specificity, limited persistence of the engineered cells in the body, and the suppressive tumor microenvironment.21PubMed Central. Current status and future challenges of CAR-T cell therapy for osteosarcoma Other immune-based strategies, including bispecific antibodies, are also in active clinical development.22PubMed Central. Advances on immunotherapy for osteosarcoma The RB1 mutation story offers a parallel line of hope: osteosarcoma cells that have lost RB1 function are poor at repairing their own DNA, making them vulnerable to drugs called PARP inhibitors that exploit that repair deficit. In laboratory studies, PARP inhibitors caused extensive cell death in RB1-deficient osteosarcoma cells and prolonged survival in animal models.23Nature Communications. Therapeutic vulnerability to PARP1,2 inhibition in RB1-mutant osteosarcoma
Monitoring for Recurrence With Liquid Biopsies
After treatment, patients undergo regular imaging to watch for recurrence, typically chest CTs and scans of the original tumor site. An emerging tool that could change surveillance is the liquid biopsy: a blood draw that detects tiny fragments of tumor DNA circulating in the bloodstream. Researchers have shown that tumor-specific mutations identified in the original biopsy can be tracked in these blood samples.24PubMed Central. Detection of circulating tumor DNA in patients with osteosarcoma
A prospective study found that patients whose circulating tumor DNA (ctDNA) became negative or stayed negative after surgery had significantly better outcomes, while a positive ctDNA result carried roughly seven to eight times the risk of relapse or progression. In five patients, the blood test flagged recurrence an average of about 93 days earlier than imaging did.25eClinicalMedicine. Tumor-informed circulating tumor DNA for minimal residual disease surveillance and recurrence monitoring in osteosarcoma: a prospective cohort study That lead time could allow earlier intervention, though clinical trials are still needed to prove that acting on a ctDNA signal rather than waiting for visible disease on a scan actually improves survival. The technology is not yet standard of care, but it is being watched closely.
Life After Osteosarcoma
Surviving osteosarcoma is only part of the story. A long-term follow-up of over 1,250 survivors tracked for an average of about 24 years found that roughly 13% had died from late causes by the twenty-year mark. Compared to their siblings, survivors had nearly four times the rate of chronic health conditions, with particularly elevated risks for cardiac problems, hearing loss, and musculoskeletal issues. Patients who received MAP chemotherapy had about twice the risk of severe chronic health conditions compared to those who received no chemotherapy, reflecting the real toll of the drugs that saved their lives.26PubMed Central. Long-term outcomes among survivors of childhood osteosarcoma: A report from the Childhood Cancer Survivor Study (CCSS)
Physical limitations are common. A British study found that over half of bone sarcoma survivors were limited in moderate physical activities and in walking more than a mile, compared to fewer than one in ten in the general population. Pain remained a persistent issue, and survivors who had undergone amputation reported the greatest physical limitations.27PubMed Central. Long-term adverse outcomes in survivors of childhood bone sarcoma: The British Childhood Cancer Survivor Study On the cognitive side, about 41% of adult survivors evaluated in one study had severe or life-threatening chronic conditions in cardiac, pulmonary, or endocrine categories, and those individuals performed significantly worse on tests of memory and processing speed compared to survivors with milder chronic problems.28JAMA Oncology. Neurocognitive and Patient-Reported Outcomes in Adult Survivors of Childhood Osteosarcoma The chemotherapy agents used against osteosarcoma are potent cardiotoxins and ototoxins, so these findings are not unexpected, but they underscore the need for lifelong monitoring.
The psychological toll also deserves attention. For patients who undergo amputation, body image and self-worth can take a significant hit. Survivors have described amputation as feeling like a life-ending event, reporting feelings of inferiority that contributed to lasting psychological distress.29PubMed. Effects of amputation on the mental health among osteosarcoma survivors: A mixed quantitative study at a city-based corporate hospital in India Access to mental health support and peer networks appears to help, but these services are not always built into follow-up care.
Global Disparities in Osteosarcoma Care
Where you live can dramatically alter your odds. A scoping review of osteosarcoma care across Africa found that 81% of patients presented with locally advanced or metastatic disease, a far higher proportion than in high-income countries where earlier detection is more common. Only about half of surgical patients underwent limb-salvage procedures, with amputation remaining the norm. The pooled five-year overall survival was about 49%, held back by late presentation, shortages of trained surgeons and oncologists, limited access to chemotherapy drugs, high out-of-pocket costs, and cultural factors including reliance on traditional healers.30ecancermedicalscience. Challenges of osteosarcoma care in Africa: a scoping review of the burden, management and outcome The gap between what is achievable with modern multidisciplinary care and what is available in low-resource settings remains one of the starkest inequities in cancer medicine.
What Dogs Are Teaching Researchers
Osteosarcoma is not just a human disease. Large and giant breed dogs develop it at rates far higher than people do, and the canine version looks strikingly similar in terms of location, behavior, and biology. Dogs with osteosarcoma develop tumors in the same long bones, experience the same tendency toward lung metastasis, and respond to similar chemotherapy agents. Because of this overlap and the much higher incidence in dogs, veterinary patients serve as a parallel population that can accelerate research into new treatments for both species.31PubMed Central. Canine osteosarcoma in comparative oncology: Molecular mechanisms through to treatment discovery Genetic studies in dogs, where breed-specific risks allow researchers to narrow down susceptibility genes more quickly, have the potential to shed light on human osteosarcoma as well.32PubMed Central. Comparative review of human and canine osteosarcoma: morphology, epidemiology, prognosis, treatment and genetics
An Ancient Disease
If osteosarcoma feels like it should be a modern problem, a product of something in our environment or lifestyles, it is not. Researchers have identified osteosarcoma in a 240-million-year-old fossil of a stem-turtle from the Triassic period, making it one of the oldest documented cancers in the vertebrate fossil record.33PubMed Central. Triassic Cancer—Osteosarcoma in a 240-Million-Year-Old Stem-Turtle The finding reinforces that cancer is not a defect of modernity but a deeply embedded vulnerability in any organism that grows by dividing cells. For osteosarcoma specifically, where rapid bone growth is the clearest risk factor, the connection makes intuitive sense: as long as animals have been building skeletons, those skeletons have occasionally built tumors.